When conflict-of-interest is a factor in scientific misconduct

Medicine and Law

Volumn 26, Issue 3, 2007, Pages 447-463

  Krimsky, Sheldon ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Conflict of interest; Ghostwriting; Office of research integrity (USA); Vigor study

Indexed keywords

ANTIDEPRESSANT AGENT; CELECOXIB; NAPROXEN; ROFECOXIB;

ARTICLE; AUTHOR; CLINICAL TRIAL; COMMERCIAL PHENOMENA; CONFIDENTIALITY; CONFLICT OF INTEREST; CRIMINAL BEHAVIOR; DEPRESSION; DRUG LEGISLATION; DRUG RESEARCH; DRUG SAFETY; FINANCIAL MANAGEMENT; FORGERY; HEART INFARCTION; HUMAN; INTERPERSONAL COMMUNICATION; MEDICAL ETHICS; MEDICAL LITERATURE; MEDICAL PRACTICE; MEDICAL RESEARCH; MEDICAL SOCIETY; PATENT; PRACTICE GUIDELINE; PROFESSIONAL MISCONDUCT; PUBLICATION; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SCIENTIFIC MISCONDUCT; STOMACH ULCER;

CONFLICT OF INTEREST; DISCLOSURE; HUMANS; SCIENTIFIC MISCONDUCT; UNITED STATES;

EID: 35449006723     PISSN: 07231393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. D.F. Thompson. Understanding financial conflicts of interest. New England Journal of Medicine 329:573-576 (1993).
2. P.M. Tereskerz and J. Moreno. Ten steps to developing a national agenda to address financial conflicts of interest in industry sponsored clinical research. Accountability in Research 12:139-155 (April-June 2005), p. 143.
3. Sheldon Krimsky. Autonomy, disinterest, and entrepreneurial science. Society 43(4):22-29 (May/June 2006).
4. Richard Smith. What is Research Misconduct? A background paper prepared for the joint consensus conference on misconduct in biomedical research. http://www.rcpe.ac.uk/publications/articles/supplement7_misconduct/ C_what_is_research_misconduct.pdf
5. David J. Cullin. Ghostwriting in scientific anesthesia journals. Anesthesiology 87:195-196 (August 1997).
6. Cullen, 1997, p. 196.
7. Antony Barnet, public affairs editor. Revealed: How drug firms 'hoodwink' medical journals. The Observer, December 7, 2003.
8. Sarah Boseley. Scandal of scientists who take money for papers ghostwritten by drug companies. The Guardian, February 7, 2002.
9. David J. Cullen. Ghost writers in scientific anesthesiology journals. Anesthesiology 7(2)1:195-196 (August 1997).
10. A. Flanagan, L.A. Carey, P.B. Fontanarose et al. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA 280(3):222-224 (July 15, 1998).
11. Peter C. Gøtzsche, HrÓbjartsson, AsbjÓrn, Johansen, Helle Krogh et al, Ghost authorship in industry-initiated randomized trials. PLOS Medicine 4(1):6Pp (January 2007).
12. Frank Frizelle. Research dishonesty and conflict of interest. The New Zealand Medical Journal 115:1-3 (December 13, 2002), p. 2.
13. S. Ngai, J.L. Gold, S.S. Gill et al. Haunted manuscripts: Ghost authorship in the medical literature. Accountability in Research 12:103-114 (April-June, 2005), p. 104.
14. Ngai, 2005, pp. 108-110.
15. Elke Brüser. Interview with John Rengen, former business head for Eli Lilly in Sweden. Iche habe Menschen bestochen. Die tageszeitung. January 12, 2007.
16. Richard A. Knox. Biomedical results are often withheld. Boston Globe April 16, 1997.
17. Gardiner Harris, F.D.A. says Bayer failed to reveal drug risk study. New York Times September 30, 2006.
18. C.G. Whittington, T. Kendall, P. Fonagly et al. Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. The Lancet 363(9418):1341-1345 (April 24, 2004).
19. Whttington et al. 2004, p. 1341.
20. K. Dickersin and D. Rennie. Registering clinical trials. JAMA 290:516-523 (July 23/30, 2003).
21. International Committee of Medical Journal Editors (ICMJE), website. http://weww.icmje.org. Accessed June 7, 2007.
22. J. B. Hrachovec and Marc Mora. Reporting of 6-month vs 12-month data in a clinical trial of Celecoxib. JAMA 286(19):2398 (November 21, 2001).
23. G.D. Curfman, S. Morressey, and J.M. Drazen. Expression of concern: Bombardier et al. Comparison of upper gastrointestinal toxicity of Rofecoxib and Naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 343(21):1520-1528 (November 23,2000).
24. Marion E. Broome. Scientific integrity-the cornerstone of knowledge. Journal of Neuroscience Nursing 35(1):56-59 (2003)
25. ICMJE website. http://weww.icmje.org. Accessed June 7, 2007.
26. K.A. Schulman, D.M. Seils, J.W. Timbie et al. A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N.. Engl. J Med. 347(17):1335-1341 (October 24, 2002).
27. Sheldon Krimsky. Science in the Private Interest. Lanham, MD: Rowman & Littlefield, Pub., 2003, p. 118.
28. Krimsky, 2003, p. 120.
29. Jerry Ravetz. Scientific Knowledge and its Social Problems. Oxford University Press, 1971. Oxford, UK.
30. Deborah Parrish. The scientific misconduct definition and falsification of credentials. Professional Ethics Report IX: 1-5 (Fall 1996).
31. Website of the U.S. Office of Research Integrity. http://ori.dhhs.gov/ final/search/php. Accessed May 7, 2007.
32. http://ori.hhs.gov/misconduct/cases/investigatio_summ_1994.shtml Accessed May 7,2007.
33. H.C. Sox, D. Rennie. Research misconduct, retraction and cleaning the medical literature: Lessons from the Poehlman case. Annals of Internal Medicine 144(8):609-613 (April 18,2006).
34. R. Smith. What is research misconduct? A background paper prepared for the joint consensus conference on misconduct in biomedical research. J. Royal College of Physicians Edinborough. 30:4-8 (2000).
35. Christopher J Borgert. Letter. Conflict of interest: Kill the messenger or follow the data? Environmental Science & Technology 41(3):665-666 (February 1, 2007), p. 665.
36. Borgert, 2007, p. 665.
37. Krimsky, Sci. & Priv. Int., 2003.
38. D.E. Barnes, L.A. Bero. Why review articles on the health effects of passive smoking reach different conclusions. JAMA 279(19):1566-1570 (May 20, 1998).
39. J. Levine, J.D. Gussow, D. Hastings, and A. Eccher. Authors' financial relationships with the food and beverage industry and their published positions on the fat substitute Olestra. American Journal of Public Health 93:664-669 (April 23).
40. J.E. Bekelman, Y. Li, and C.P. Gross. Scope and impact of financial conflicts of interest in biomedical research: A systematic review. JAMA 289(4):454-465 (January 22/29,2003), p. 463.
41. H.T. Stelfox, G. Chua, K. O'Rourke et al. Conflict of interest in the debate over calcium-channel antagonists. NEJM 338:101-106 (January 8, 1998).
42. S. Krimsky. A conflict of interest. New Scientist 179:21 (August 30, 2003).
43. David Armstrong. Surgery journal threatens ban for author's hidden conflicts. Wall Street Journal December 28, 2005, p. B1.
44. K. Mangan and J.R. Young. Medical journal toughens its conflict-of-interest policy. July 21, 2006. http://chronicle.com/ weekly/v52/i46/46a014101.htm. Accessed May 13, 2007
45. Krimsky, Sci. & Priv. Int., 2003, p. 134.